Skip to main content
OFFICIAL STATEMENT · SWITZERLAND

Official Endopeel Safety Statement

Scientific Clarification · Authenticity · Traceability · Patient Safety

Endopeel is the designation of a set of specific medical techniques, not the generic name of an injectable substance. This official statement clarifies the distinction between the original techniques, their historical formulation and preparations of unverified origin marketed under the Endopeel name.

Scientific Integrity Product Authenticity Medical Training Patient Safety
Issued by
Dr. Alain Tenenbaum, M.D., Ph.D., D.Sc.
Mauro Tiziani, B.Sc

Inventors and Developers of Endopeel Techniques
Switzerland

In 30 Seconds

Four Essential Facts Everyone Should Know
01

Techniques, Not a Generic Product

Endopeel designates a set of specific medical techniques. It is not the generic name of an injectable chemical substance.

02

The Historical Original Formulation

DocTNB was the historical formulation associated with the original techniques. Its identity cannot be established by a commercial name alone.

03

Unverified Preparations

Preparations marketed as Endopeel or Hidroxibenceno cannot be presumed equivalent to the original formulation without appropriate scientific verification.

04

Training and Patient Safety

Specific medical training, product authentication, traceability, regulatory compliance and informed consent are essential considerations for patient safety.

A shared commercial designation does not establish chemical equivalence, clinical safety or authenticity.

Endopeel Is Not a Generic Product

Understanding the Difference Between a Medical Technique and a Chemical Formulation

Endopeel was developed as a set of specific medical techniques involving muscle and skin retensioning and three-dimensional reshaping. It does not designate a generic injectable substance or a standardized pharmaceutical ingredient.

ORIGINAL MEDICAL CONCEPT

Endopeel Techniques

A specific medical approach developed by Dr. Alain Tenenbaum and Mauro Tiziani, incorporating:

  • Chemical myoplasty.
  • Chemical myopexy.
  • Chemical myotension.
  • Specific anatomical and clinical knowledge.
  • Dedicated medical education and training.
NO AUTOMATIC EQUIVALENCE

Injectable Preparations

A preparation marketed under the Endopeel name cannot automatically be identified as the original historical formulation.

  • A commercial name is not a chemical identity.
  • Similar ingredients do not establish equivalence.
  • Manufacturing origin requires verification.
  • Product authenticity requires documentation.
  • Clinical safety cannot be inferred from branding.
FUNDAMENTAL DISTINCTION

The use of the Endopeel name does not, by itself, establish the identity of an injected substance, its authenticity or conformity with the original medical techniques.

The Original DocTNB Formulation

Historical Identity · Scientific Documentation · Authenticity
🔒
PROTECTED ARCHIVAL DOCUMENTATION

Original DocTNB Packaging

The original packaging is intentionally not displayed. According to our historical records, its appearance has previously been imitated. This precaution aims to reduce the risk of further unauthorized reproductions.

HISTORICAL REFERENCE

A Specific Historical Formulation

DocTNB was the historical formulation associated with the development of the original Endopeel techniques by Dr. Alain Tenenbaum and Mauro Tiziani.

Its scientific identity cannot be reduced to a generic chemical designation or established solely through the use of the Endopeel name.

According to the inventor's historical records, the original DocTNB formulation was no longer commercially available in 2019.

01

Formulation Identity

Chemical identity requires appropriate analytical documentation, including relevant stereochemical and physicochemical characteristics.

02

Historical Traceability

Authentication requires reliable manufacturing records, provenance, batch identification and supporting documentation.

03

Scientific Non-Equivalence

Experimental observations concerning DocTNB cannot automatically be extrapolated to other preparations of unverified composition.

IMPORTANT HISTORICAL CLARIFICATION

The presence of the Endopeel name on a preparation does not constitute proof that it is the original DocTNB formulation. Authenticity and clinical safety require independent verification.

THE NEXT CHAPTER

The Original Concept Continues

Updated Formulation · Controlled Professional Access

The discontinuation of the historical DocTNB formulation does not mark the end of the original medical concept.

According to Styling Cosmetics AG, an updated magistral formulation is available within its current European supply framework, involving a designated compounding pharmacy.

This framework distinguishes professional licensing from the pharmaceutical responsibilities of the designated pharmacy.

Its objectives are formulation integrity, authenticity, traceability and controlled professional access.

A commercial licence does not replace any required medical or pharmaceutical authorization. Availability remains subject to applicable national regulations.

Professional Licensing Information ↗
INTERNATIONAL SAFETY NOTICE

Unauthorized Preparations & Misuse of the Endopeel Name

Protecting Scientific Integrity and Patient Safety

Over the years, the developers of Endopeel have received reports of preparations marketed under the Endopeel name without their authorization or verification of chemical equivalence to the original formulation. Particular concerns have arisen in Latin America ( Argentina, Uruguay,Ecuador), Spain and Turkey.

Misuse of the Endopeel Name

The use of the Endopeel designation on a label, website or commercial document does not establish any association with the original developers, formulation or medical techniques.

Unverified Pharmaceutical Preparations

A preparation described as magistral does not automatically establish its authenticity, chemical equivalence or regulatory compliance. Its origin and quality must be independently verifiable.

Uncontrolled Online Distribution

Particular concern arises when injectable preparations are offered online without adequate verification of the supplier, pharmaceutical provenance or professional qualifications of the purchaser.

Unknown Composition and Clinical Risks

Preparations of unverified composition may present unpredictable clinical risks. Similar names, packaging or claimed ingredients cannot establish pharmaceutical equivalence or clinical safety.

A Matter of Patient Safety

Authenticity Cannot Be Assumed

Medical professionals should not use injectable preparations whose identity, provenance, pharmaceutical quality and regulatory status cannot be reliably established.

Suspected unauthorized preparations and potentially illegitimate commercial distribution should be reported to the competent national health authorities.

However, the effectiveness, transparency and independence of regulatory oversight may vary considerably between countries. Regulatory failures and inadequate enforcement remain major concerns for patient safety.

FUNDAMENTAL SAFETY PRINCIPLE

A commercial designation is not a certificate of authenticity, pharmaceutical quality or clinical safety.

SCIENTIFIC CLARIFICATION

Hidroxibenceno & Chemical Identity

Chemical Terminology Does Not Establish Pharmaceutical Equivalence

The term Hidroxibenceno has been encountered in connection with preparations marketed in Latin America. This chemical designation must not be confused with the identity of the original DocTNB formulation or with the original Endopeel medical techniques.

Original DocTNB

A specific historical pharmaceutical formulation, associated with documented research and the development of the original Endopeel techniques. Its identity requires formulation-specific analytical documentation.

≠

Hidroxibenceno

A chemical designation which, by itself, provides no evidence of equivalence to the original DocTNB formulation, its pharmaceutical quality or its clinical properties.

Why Chemical Identification Matters

Chemical nomenclature, molecular identity, stereochemical characteristics, formulation composition and pharmaceutical quality are distinct scientific considerations.

Equivalence between preparations cannot be presumed on the basis of a shared ingredient, a similar chemical name or a commercial designation.

Such equivalence requires appropriate analytical evidence and independent scientific assessment.

Scientific Evidence & Its Limitations

Conduction Velocity · Muscle Fiber Organization · Experimental Follow-up

The historical DocTNB research programme included electrophysiological measurements and histological investigations to assess functional and structural tissue responses over time.

EXPERIMENTAL ELECTROPHYSIOLOGY

Changes in Conduction Velocity Over Time

Historical experimental conduction velocity measurements comparing DocTNB and NaCl over 28 days
Historical experimental data. Courtesy of Dr. Alain Tenenbaum and Mauro Tiziani.

The recorded measurements show an initial reduction in conduction velocity followed by progressive recovery during the 28-day experimental observation period.

9.11

Day 0 — Baseline

7.46

Day 1 — Initial Reduction

8.62

Day 28 — Progressive Recovery

EXPERIMENTAL HISTOLOGY

Muscle Fiber Disorganization and Reorganization

Historical histological section illustrating muscle fiber structural changes
Histological documentation from the original DocTNB research archives.

This historical histological image illustrates changes in muscle fiber organization during the initial experimental tissue response.

According to the original investigators, subsequent muscle fiber reorganization was observed without reported necrosis in the examined specimens. Further histological documentation is available here.

The Limits of Experimental Evidence

Scientific Observations Require Methodological Context

These historical experimental observations must be interpreted within the context of their original research protocols and conditions.

The available conduction velocity measurements demonstrate progressive recovery, before complete normalization by day 28. Experimental findings establish universal clinical safety and exclude adverse effects.

Medical Training & Professional Responsibility

Education · Clinical Competence · Medical Ethics

Endopeel was developed as a specialized medical discipline requiring dedicated education, clinical judgment and an understanding of its scientific and anatomical foundations.

Technique-Specific Medical Education

General experience in aesthetic medicine does not necessarily establish competence in a specialized medical technique. Appropriate education and supervised training are essential.

Clinical Judgment

Each practitioner remains responsible for individual patient assessment, indication selection, recognition of contraindications and appropriate clinical decisions.

Informed Consent

Patients must receive understandable information concerning the proposed procedure, its potential benefits, limitations, alternatives and foreseeable risks before providing consent.

Clinical Follow-up

Professional responsibility continues beyond the procedure itself and includes appropriate follow-up, assessment of unexpected symptoms and management or referral of complications.

PROFESSIONAL TRAINING RECORDS

Verification of Original Endopeel Training

Attendance at original Endopeel training programmes organized by Dr. Alain Tenenbaum or his authorized representatives may be verified against available historical training records.

The use of the Endopeel name by a practitioner does not, by itself, establish participation in these educational programmes.

Today, the original educational programme has evolved into customized medical training in Myomodulation, incorporating more sophisticated technical concepts and individualized approaches to muscle and skin retensioning and three-dimensional reshaping.

Knowledge Cannot Be Substituted

Medical Education Is an Essential Professional Responsibility

A training certificate, commercial licence or professional title cannot replace demonstrated clinical competence, sound medical judgment and individual professional responsibility.

Product Authenticity, Traceability & Patient Safety

Documentary Verification Before Clinical Use

Traceability establishes a documented connection between a pharmaceutical preparation, its origin and its clinical use. Reliable records are essential for investigating suspected product irregularities and adverse events.

01

Pharmaceutical Provenance

Verify the identity of the pharmaceutical establishment responsible for the preparation and retain the corresponding documentation.

02

Preparation Identification

Maintain accurate records of the preparation identifier, dispensing date and relevant pharmaceutical documentation.

03

Documented Chain of Supply

Preserve records linking the pharmaceutical source to the dispensing and receiving healthcare professionals.

04

Clinical Documentation

Record the preparation used in the patient file to support clinical follow-up, pharmacovigilance and adverse event assessment.

EVIDENCE PRESERVATION

When Product Authenticity Is Questioned

Preserve the available packaging, labels, invoices, preparation identifiers and supplier correspondence for appropriate investigation.

Relevant documentation should be made available to the competent authorities and qualified independent investigators, where appropriate.

When in Doubt, Do Not Use

Patient Safety Takes Priority

If the identity, provenance or regulatory status of a preparation cannot be established, its clinical use should not proceed pending appropriate verification.

Report a Suspicious Product →
OFFICIAL QUESTIONS & ANSWERS

Frequently Asked Questions

Clear Answers · Scientific Information · Patient Safety

Answers to essential questions concerning the original Endopeel techniques, pharmaceutical authenticity, professional education and safety considerations.

01 Is Endopeel the name of an injectable product?

No. Endopeel designates a set of specific medical techniques developed by Dr. Alain Tenenbaum and Mauro Tiziani. It is not a generic pharmaceutical substance.

Read the official definition.

02 Is the historical DocTNB formulation still available?

The historical formulation has been discontinued. According to Styling Cosmetics AG, an updated magistral formulation exists within its current professional supply framework, subject to applicable national regulations.

Read about the current framework.

03 Is Hidroxibenceno equivalent to DocTNB?

The designation Hidroxibenceno does not establish pharmaceutical equivalence to DocTNB. Such equivalence would require appropriate analytical documentation.

04 Can a product be authenticated from its packaging alone?

No. Packaging, labels and commercial names may be reproduced or imitated. Authentication requires reliable documentation of pharmaceutical origin and traceability.

05 Does a commercial licence establish medical competence?

No. Commercial licensing, professional qualifications and technique-specific medical training are distinct matters. Practitioners remain responsible for their clinical competence and medical decisions.

06 Can original experimental findings be applied to other formulations?

No automatic extrapolation can be made. Experimental results must be interpreted according to the preparation studied, the research methodology and the original experimental conditions.

Review the historical scientific documentation.

07 Can participation in original training programmes be verified?

Verification may be requested on the basis of available historical training records maintained by the original organizers.

08 What should I do if I encounter a suspicious preparation?

Do not use the preparation pending verification. Preserve relevant documentation and report your concerns through the appropriate safety channels.

Access the product safety reporting section.

OFFICIAL COMMUNICATION CHANNEL

Scientific Enquiries & Product Safety Reporting

Scientific Integrity · Professional Dialogue · Responsible Reporting

Healthcare professionals, scientific institutions, regulatory authorities and members of the press may contact us for documentary clarification concerning the original Endopeel techniques.

Scientific & Documentary Enquiries

Request information concerning historical research, scientific documentation, formulation identity or professional training records.

Submit a Safety Report →

Report a Suspicious Preparation

Communicate concerns regarding suspected unauthorized use of the Endopeel name, product authenticity or pharmaceutical provenance.

Submit a Safety Report →
CONFIDENTIALITY & RESPONSIBLE REPORTING

Please do not include identifiable patient data in your initial correspondence. This communication channel does not replace medical consultation, emergency care or official regulatory reporting.

Dr. Alain Tenenbaum, M.D., Ph.D., D.Sc.
Mauro Tiziani B.Sc

Inventors and Developers of Endopeel Techniques
Switzerland

STYLING COSMETICS AG · SWITZERLAND